Background/aim: We evaluated the efficacy of primary prophylaxis with pegfilgrastim (PEG) for febrile neutropenia (FN) in small cell lung cancer (SCLC) patients receiving amrubicin (AMR).

Patients And Methods: A retrospective cohort study was conducted in patients with SCLC receiving AMR as second-line therapy.

Results: A total of 33 patients were treated with AMR (no PEG group), while 13 patients were treated with AMR plus prophylactic administration of PEG (PEG group). The severity of neutropenia was significantly reduced in the PEG group compared to the no PEG group (p=0.02). The incidence of FN in the no PEG and PEG groups was 27.3% and 7.7%, respectively. The time to development of FN tended to be longer in the PEG group compared to the no PEG group (p=0.132).

Conclusion: Primary prophylaxis with PEG may be beneficial in reducing the risk of FN in patients with SCLC receiving AMR.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14923DOI Listing

Publication Analysis

Top Keywords

peg group
24
primary prophylaxis
12
peg
11
febrile neutropenia
8
lung cancer
8
patients receiving
8
receiving amrubicin
8
patients sclc
8
sclc receiving
8
receiving amr
8

Similar Publications

In this study, polyethylene glycol (PEG) and dextran (Dex) were chemically modified to obtain amino-functionalized PEG (PEG-(NH)) and oxidized dextran (ODex). They were subsequently reacted via -NH and -CHO groups to synthesize a macromolecular Schiff base particle. The structures, morphologies, and thermal properties of the macromolecular Schiff base particle were characterized using Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), and thermogravimetry analysis (TGA).

View Article and Find Full Text PDF

Backround: Manual therapy techniques are available for pain management in Multiple Sclerosis (MS); however, the results of neurodynamic mobilization (NM) are not known. The aim of this study was to investigate the effects of NM exercises on pain, muscle strength and upper extremity functions in MS patients.

Methods: Patients aged between 18 and 65 years diagnosed with Relapsing Remitting (RR) MS (n = 31) according to McDonald 2010 diagnostic criteria were included in the study.

View Article and Find Full Text PDF

Significance: Artificial tears remain the cornerstone for managing dry eye disease. The current study's real-world efficacy test of carboxymethylcellulose (CMC), polyethylene glycol (PEG) 400, or sodium hyaluronate (SH)-based lubricants highlights their similar effects on noninvasive tear film parameters over the short term. However, patients reported better relief with SH-based lubricants.

View Article and Find Full Text PDF

Development of a Peptide-Based Tumor-Activated Checkpoint Inhibitor for Cancer Immunotherapy.

Acta Biomater

December 2024

Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA. Electronic address:

Antibody-based checkpoint inhibitors have achieved great success in cancer immunotherapy, but their uncontrollable immune-related adverse events remain a major challenge. In this study, we developed a tumor-activated nanoparticle that is specifically active in tumors but not in normal tissues. We discovered a short anti-PD-L1 peptide that blocks the PD-1/PD-L1 interaction.

View Article and Find Full Text PDF

Highly porous, self-supported 3D interconnected network-based nanomaterials hold immense promise in revolutionizing the field of catalysis. These materials combine two critical features; a large accessible surface and an overall active surface that leads to substantial catalytic effects. In this study, we developed a novel class of 3D composite material composed of zinc oxide tetrapods (ZOT) and polyethylene glycol (PEG) polymer, specifically designed for photocatalysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!